A Silent Killer That India Can Finally Outpace
Every eight minutes, an Indian woman dies of cervical cancer. That is not a statistic you read and move on from — that is a mother, a daughter, a teacher, a health worker. And the most disturbing part? Nearly every one of those deaths is preventable.
On 28 February 2026, Prime Minister Narendra Modi launched India’s first-ever nationwide HPV (Human Papillomavirus) vaccination campaign — one of the most significant preventive public health interventions the country has seen in recent memory. Free of cost. At government health facilities across every state and union territory. Targeting adolescent girls aged 14 years, with a three-year catch-up phase for the 9–14 age group.
This is not just a vaccine rollout. This is India taking a long-overdue, evidence-backed stand against a cancer that has long disproportionately burdened its women.
The Scale of India’s Cervical Cancer Burden
The numbers demand attention:
- India records approximately 1,23,000 new cervical cancer cases every year — making it the second most common cancer among women in the country.
- Nearly 75,000 Indian women die from cervical cancer annually, accounting for one-fourth of all cervical cancer deaths worldwide.
- The disease causes 1.37 million Disability-Adjusted Life Years (DALYs) lost — a devastating toll on productivity, family welfare, and the healthcare system.
- India’s age-standardised incidence rate stands at 17.71 per 1,00,000 women — second only to sub-Saharan Africa.
- Cervical cancer screening coverage remains under 5%, and vaccination coverage before 2022 was near zero.
HPV types 16 and 18 are responsible for 70% of cervical cancers globally and a staggering 85% of cases in India. The vaccine directly targets these high-risk strains.
What Is the HPV Vaccine and How Does It Work?
The Gardasil-4 vaccine — the one being administered under this national programme — is a recombinant, non-infectious vaccine that uses virus-like particles (VLPs). These are harmless copies of the virus’s outer protein shell, engineered to train the immune system to recognise and destroy the actual HPV virus if encountered later.
Gardasil-4 protects against four HPV types:
- Types 16 and 18 — responsible for the majority of cervical cancers
- Types 6 and 11 — responsible for most genital warts
Importantly, the vaccine does not contain live virus and cannot cause HPV infection or cervical cancer. It is WHO pre-qualified and has been used in immunisation programmes globally for over a decade.
Why a Single Dose? The Science Behind the Decision
Earlier schedules required two or three doses of the HPV vaccine. India’s programme adopts a single-dose schedule — and this is backed by strong evidence.
A landmark 2022 WHO review of clinical data confirmed that one dose of the HPV vaccine provides protection comparable to two or three doses in adolescent girls who receive it before any HPV exposure. This is a game-changer for implementation — fewer cold chain requirements, simpler logistics, reduced dropout rates, and significantly lower programme costs.
The target age of 14 years is specifically chosen because immunity is strongest during adolescence, and most girls in this age group have not yet been exposed to the virus. This window of opportunity, once missed, cannot be recaptured as effectively.
How the Programme Is Being Rolled Out
The Ministry of Health and Family Welfare has designed a careful, phased rollout:
- Pilot phase: Launched in Uttar Pradesh, Bihar, and Maharashtra — three high-burden states — before national expansion under the Universal Immunisation Programme (UIP).
- Scale-up target: 1.15 crore girls per year during a three-year catch-up phase, amounting to nearly 2.6 crore doses by 2027.
- Vaccine supply: Over 1 crore doses of Gardasil-4 are being procured through Gavi, the Vaccine Alliance, ensuring supply stability at subsidised pricing.
- Delivery points: All government primary health centres, community health centres, Ayushman Arogya Mandirs, and district hospitals.
- Digital registration: Appointments can be booked through the U-WIN digital platform, ensuring tracking and accountability.
- Cold chain compliance: Each vaccination site is equipped with a Cold Chain Point (CCP) and a designated medical officer to monitor Adverse Events Following Immunisation (AEFI).
India’s Indigenous Vaccine: CERVAVAC
Alongside the import of Gardasil-4, India has developed its own HPV vaccine — CERVAVAC — produced by the Serum Institute of India. It is India’s first indigenously developed HPV vaccine and is expected to progressively reduce programme costs, improve domestic supply security, and strengthen vaccine equity for other low- and middle-income countries in the region.
This is a proud moment for India’s biopharmaceutical capability — a country that vaccines the world now vaccinating its own daughters against a preventable cancer.
Vaccination Is Not a Replacement for Screening
A critical message that must accompany every conversation about the HPV vaccine: vaccination does not replace cervical cancer screening.
The vaccine protects against the most common high-risk HPV types, but not all. Women who are vaccinated must still undergo regular screening — through Pap smear or HPV DNA testing — especially as they enter their 20s and 30s. Combined, vaccination and at least three rounds of lifetime screening can reduce cervical cancer deaths by more than half, as modelling studies have shown.
India’s current screening coverage of under 5% is itself a public health emergency that this campaign must not overshadow. Both prevention pillars must advance together.
What This Means for India’s Public Health Trajectory
The WHO has set a global target to eliminate cervical cancer as a public health threat by 2030. For India — which carries 20% of the world’s burden — this campaign is both a national obligation and a global contribution.
If vaccine coverage reaches 80% or more and is sustained over the coming decade, epidemiological projections suggest India could prevent hundreds of thousands of cervical cancer deaths in the next 20–30 years. This is a long-horizon intervention — the payoff will not be visible in the next election cycle, but it will be felt in the lives of millions of girls now in school who will grow into healthy women.
This is what preventive public health looks like at scale. Evidence-informed. Equity-driven. Delivered through public systems to those who need it most.
What Families, Schools, and Healthcare Workers Must Do Now
- Spread accurate information: Vaccine hesitancy, often rooted in misinformation about safety or side effects, remains the biggest implementation risk. Community-level communication must be proactive and culturally sensitive.
- Ensure all eligible girls are registered: Use U-WIN to book appointments. School health programmes and ANMs should actively track 14-year-old girls in their catchment areas.
- Reassure parents: The vaccine is safe, non-live, WHO pre-qualified, and has been used in over 100 countries. Mild soreness at the injection site is the most common side effect.
- Emphasise continued screening: Vaccinated girls must know they still need regular cervical screening when they are older.
- Document and monitor AEFI: Healthcare providers should follow standard AEFI surveillance protocols and report any adverse events promptly.
The Bottom Line
India has taken a decisive, courageous step. For a country where cervical cancer has long been a silent killer — stigmatised, under-screened, and under-vaccinated — a free, nationwide, single-dose HPV vaccination programme is nothing short of transformative.
The question now is not whether the vaccine works. It does. The question is whether our public health systems, communities, and communicators can work together to ensure every eligible girl in India gets her shot.
Because the science is ready. The vaccine is ready. Now it is our turn.
Sources: Ministry of Health and Family Welfare, Government of India; Gavi, the Vaccine Alliance; WHO HPV vaccination guidelines 2022; Indian Journal of Public Health; Organiser.org; Diplotic.com; India TV News
